Clinical Trial Update: A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C [Phase 3]

View source ↗

Summary

Phase 3 study evaluating peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Chugai Pharmaceutical | Conditions: Chronic Hepatitis C | Phase 3 | Status: COMPLETED